In patients with chronic hepatitis B virus (HBV) infection, tenofovir alafenamide (TAF) shows comparable 96-week efficacy and improved renal and bone safety with tenofovir disoproxil fumarate (TDF), a recent study has shown.
It appears that urgent repeat endoscopic retrograde cholangiopancreatography (ERCP) predicts failure of plastic stent treatment for biliary strictures (BS) following liver transplant, according to a study.
In patients with cirrhosis, 8 weeks of a home-based exercise training (HET) regimen effectively improves exercise capacity, peak aerobic power (peak VO2) and 6-minute walk distance (6MWD), particularly in those with high adherence, a recent study has shown.
Periodontitis is associated with nonalcoholic fatty liver disease (NAFLD), a recent epidemiological study has shown, adding that the presence of significant liver fibrosis makes this association more robust.
Age appears to not significantly impact treatments and outcomes for hepatocellular carcinoma (HCC), a new study reveals. Survival is comparable between older and younger patients, and equally active treatments should be administered to both age groups.
Triglyceride and glucose index in combination with body mass index (TyG-BMI) is an effective marker in detecting nonalcoholic fatty liver disease (NAFLD) in nonobese individuals, a new observational study has found.
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.